Alexion Pharmaceuticals (ALXN -2%) plans to launch a late-stage study, CHAMPION-ALS, this quarter evaluating Ultomiris (ravulizumab-cwvz) in patients with amyotrophic lateral sclerosis (ALS).
The primary endpoint of the 350-subject study will be the change from baseline in a scale called ALSFRS-R.
Ravulizumab is a complement inhibitor currently approved in the U.S. for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.